Results 51 to 60 of about 154,650 (346)
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease : a systematic review [PDF]
Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world. There is a strong association of NAFLD with insulin resistance and, hence, insulin sensitisers have been tried.
C Clar +21 more
core +1 more source
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu +20 more
wiley +1 more source
Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis
EtOH causes leaky gut allowing bacteria and PAMPs into the liver, resulting in hepatic inflammation and injury. We demonstrate that LPS induces STAT1‐mediated expression and phosphorylation of MLKL in macrophages and identify a novel function that myeloid MLKL translocates to phagosomes and lysosomes and regulates phagocytosis, which contributes to the
Xiaoqin Wu +16 more
wiley +1 more source
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most common liver diseases that results from excess fat accumulation in the hepatocytes. The progression of steatosis to hepatocellular necrosis and inflammation leads
Samaneh Olapour, Hamid Yaghooti
doaj
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran +17 more
wiley +1 more source
BACKGROUND & AIMS Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver biopsies, collected the time of bariatric surgery and 1 and 5 years later ...
G. Lassailly +12 more
semanticscholar +1 more source
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
A. Sanyal +10 more
semanticscholar +1 more source
A 25-gene expression signature associates with progression of fibrosing steatohepatitis in independent NAFLD cohorts. Gene expression during disease progression Nonalcoholic fatty liver disease (NAFLD) manifests as an array of conditions ranging from ...
O. Govaere +28 more
semanticscholar +1 more source
Pathologists have long been involved in clinical diagnosis and investigative studies of various forms of liver disease, including alcoholic liver disease. The concept that progressive fatty liver disease may result from causes other than alcohol toxicity can be noted in the literature.
Brunt, EM, Tiniakos, DG
openaire +3 more sources
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
Improved mitochondrial activity, due to the lack of methylation‐controlled J protein (MCJ), creates a specific microbiota signature that when transferred through cecal microbiota transplantation delays NASH progression by restoring the gut‐liver axis and enhancing hepatic fatty acid oxidation.
María Juárez‐Fernández +18 more
wiley +1 more source

